Journal article
The Australian Genetics of Depression Study: New Risk Loci and Dissecting Heterogeneity Between Subtypes
BL Mitchell, AI Campos, DC Whiteman, CM Olsen, SD Gordon, AJ Walker, OM Dean, M Berk, IB Hickie, SE Medland, NR Wray, NG Martin, EM Byrne
Biological Psychiatry | Published : 2022
Abstract
Background: Major depressive disorder (MDD) is a common and highly heterogeneous psychiatric disorder, but little is known about the genetic characterization of this heterogeneity. Understanding the genetic etiology of MDD can be challenging because large sample sizes are needed for gene discovery—often achieved with a trade-off in the depth of phenotyping. Methods: The Australian Genetics of Depression Study is the largest stand-alone depression cohort with both genetic data and in-depth phenotyping and comprises a total of 15,792 participants of European ancestry, 92% of whom met diagnostic criteria for MDD. We leveraged the unique nature of this cohort to conduct a meta-analysis with the ..
View full abstractGrants
Awarded by University of Sydney
Funding Acknowledgements
The Australian Genetics of Depression Study (AGDS) was primarily funded by the National Health and Medical Research Council (NHMRC) of Australia Grant No. 1086683, and the QSkin study was funded by the NHMRC (Grant Nos. 1073898, 1058522 and 1123248). This study was further supported by NHMRC Grant Nos. 1145645, 1078901, 1113400 and 1087889 and National Institute of Mental Health; NHMRC R.D. Wright Career Development Fellowship (1145634 [to OMD]); NHMRC Senior Principal Research Fellowship (1059660 and 1156072 [to MB]); NHMRC investigator Grant Nos. 1172917, 1173790 and 1172990 (to SEM, NRW, and NGM); NHMRC Senior Principal Research Fellowship 1155413 [to DCW]); and Trisno Family Research Fellowship (to AJW). IBH was a Commissioner in Australia's National Mental Health Commission from 2012 to 2018. He is the Co-Director, Health and Policy at the Brain and Mind Centre University of Sydney. The Brain and Mind Centre operates an early-intervention youth services at Camperdown under contract to headspace. IBH has previously led community-based and pharmaceutical industry-supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) projects focused on the identification and better management of anxiety and depression. He has led investigator-initiated studies into the antidepressant and linked circadian impacts of agomelatine. These studies have been supported by Servier, the manufacturer of agomelatine. He is the Chief Scientific Advisor to, and an equity shareholder in, InnoWell. InnoWell has been formed by the University of Sydney and PwC to pursue the transformation of mental health services through the use of innovative technologies. All other authors report no biomedical financial interests or potential conflicts of interest.